Literature DB >> 30105968

Chromobacterium violaceum in Northern Australia: A Sheep in Wolf's Clothing?

Alice Young1, Simon Smith2,3, Peter Horne4, Bronwyn Thomsett5, Josh Hanson3,6.   

Abstract

In many parts of the world, the case-fatality rate of Chromobacterium violaceum infection approaches 60%. To evaluate the spectrum of disease associated with C. violaceum in Far North Queensland (FNQ), Australia, we reviewed all culture-confirmed isolates from 1997 to 2017. There were 28 isolates, 15 represented infection, 11 were contaminants, and two charts were destroyed preventing detailed evaluation of these cases. The most common sites of infection were the skin and soft tissue and the urinary tract; there were two cases of bacteremia without focus. There were no deaths attributable to C. violaceum during the study period and only two cases required intensive care unit support, although in both patients this was not for the C. violaceum infection, but for the management of other health issues. Globally, C. violaceum has a reputation as a deadly pathogen, but in FNQ, Australia, infections usually follow a relatively benign course.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30105968      PMCID: PMC6159561          DOI: 10.4269/ajtmh.18-0311

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  17 in total

Review 1.  Chromobacterium violaceum infection: a clinical review of an important but neglected infection.

Authors:  Ching-Huei Yang; Yi-Hwei Li
Journal:  J Chin Med Assoc       Date:  2011-10-19       Impact factor: 2.743

2.  Sepsis in tropical regions: Report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine.

Authors:  Steven McGloughlin; Guy A Richards; Mohd Basri Mat Nor; Shirish Prayag; Tim Baker; Pravin Amin
Journal:  J Crit Care       Date:  2017-12-30       Impact factor: 3.425

3.  The Spectrum of Chromobacterium violaceum Infections from a Single Geographic Location.

Authors:  Yi dan Lin; Suman S Majumdar; Jann Hennessy; Robert W Baird
Journal:  Am J Trop Med Hyg       Date:  2016-02-22       Impact factor: 2.345

4.  Septicemia and death caused by Chromobacterium violaceum.

Authors:  R P Blereau
Journal:  South Med J       Date:  1980-08       Impact factor: 0.954

5.  A comparative study of virulent and avirulent strains of Chromobacterium violaceum.

Authors:  D P Miller; W T Blevins; D B Steele; M D Stowers
Journal:  Can J Microbiol       Date:  1988-03       Impact factor: 2.419

6.  Chromobacterium violaceum nosocomial pneumonia in two Japanese patients at an intensive care unit.

Authors:  Hideharu Hagiya; Tomoko Murase; Masato Suzuki; Keigo Shibayama; Yumi Kokumai; Naoto Watanabe; Miyako Maki; Fumio Otsuka
Journal:  J Infect Chemother       Date:  2013-12-11       Impact factor: 2.211

Review 7.  Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.

Authors:  R Phillip Dellinger; Jean M Carlet; Henry Masur; Herwig Gerlach; Thierry Calandra; Jonathan Cohen; Juan Gea-Banacloche; Didier Keh; John C Marshall; Margaret M Parker; Graham Ramsay; Janice L Zimmerman; Jean-Louis Vincent; Mitchell M Levy
Journal:  Crit Care Med       Date:  2004-03       Impact factor: 7.598

8.  Successful Treatment of Chromobacterium violaceum Sepsis in a South Indian Adult.

Authors:  Deepak R Madi; K Vidyalakshmi; John Ramapuram; Avinash K Shetty
Journal:  Am J Trop Med Hyg       Date:  2015-08-24       Impact factor: 2.345

9.  Urinary tract infection by chromobacterium violaceum.

Authors:  Bichitrananda Swain; Sarita Otta; Kundan Kumar Sahu; Kirtika Panda; Subhrajita Rout
Journal:  J Clin Diagn Res       Date:  2014-08-20

10.  Bacteremia and Urinary Tract Infection Caused by Chromobacterium violaceum: Case Reports from a Tertiary Care Hospital in Kathmandu, Nepal.

Authors:  Narayan Dutt Pant; Subhash Prasad Acharya; Raju Bhandari; Uday Narayan Yadav; Dil Bahadur Saru; Manisha Sharma
Journal:  Case Rep Med       Date:  2017-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.